You are here: Home » International » News » Companies
Business Standard

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal

Reuters 

Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer. The two companies said the new arrangement would give France's Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline, while U.S. healthcare group Regeneron retains all rights to its other immuno-oncology discovery and development programmes. Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal, which ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Mon, January 07 2019. 23:03 IST
RECOMMENDED FOR YOU